Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

SOMERVILLE, Mass.--(BUSINESS WIRE)--Dec 10, 2023--

Related Keywords

Massachusetts ,United States ,American ,Jess Rowlands ,Betibeglogene Autotemcel ,Courtney Oleary ,Richard Colvin ,American Society Of Hematology ,Exchange Commission ,Nasdaq ,American Society ,Annual Meeting ,Safety Results ,Improved Quality ,Life Measures ,Pediatric Patients With Transfusion Dependent ,Post Treatment With Betibeglogene Autotemcel ,Iron Burden ,Patients With Transfusion Dependent ,Treated With Betibeglogene Autotemcel ,Gene Therapy ,Neutrophil Engraftment ,Prescribing Information ,Cautionary Statement Regarding Forward Looking ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Business Wire ,National Business ,